Lasa Supergenerics Ratios

Lasa Supergenerics Ltd Ratios

The Lasa Supergenerics Ltd Ratios page provides a complete fundamental analysis of Lasa Supergenerics Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Lasa Supergenerics Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Lasa Supergenerics Ltd (NSE: LASA, BSE: 540702) is currently trading at ₹8.93, with a market capitalization of ₹441.39M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Lasa Supergenerics Ltd remains a key stock for fundamental analysis using Lasa Supergenerics Ltd Ratios.

Lasa Supergenerics Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Lasa Supergenerics Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Lasa Supergenerics Ltd Ratios.

Historically, the Lasa Supergenerics Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 10.70

The decline in Lasa Supergenerics Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Lasa Supergenerics Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.01.

Historical P/B trend:

• 2024: 1.01
• 2023: 1.14
• 2022: 0.78
• 2021: 1.32

Lasa Supergenerics Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Lasa Supergenerics Ltd P/S ratio currently stands at 0.59, an important part of Lasa Supergenerics Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.59
• 2023: 1.05
• 2022: 0.71
• 2021: 1.52

A stable or declining Lasa Supergenerics Ltd P/S ratio indicates cautious market sentiment.

Lasa Supergenerics Ltd Price to Cash Flow Ratio (P/CF)

The Lasa Supergenerics Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Lasa Supergenerics Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 1490
• 2022: 0
• 2021: 22.55
• 2020: 6.18

The declining Lasa Supergenerics Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Lasa Supergenerics Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Lasa Supergenerics Ltd EV currently stands at ₹857.58M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 857.58M
• 2023: 1.31B
• 2022: 1.12B
• 2021: 2.12B

Lasa Supergenerics Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Lasa Supergenerics Ltd EV/EBITDA ratio is currently 13.69, a key metric in Lasa Supergenerics Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 13.69
• 2023: 60.32
• 2022: 0
• 2021: 12.59

Stable Lasa Supergenerics Ltd EV/EBITDA indicates balanced valuation.

Lasa Supergenerics Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Lasa Supergenerics Ltd D/E ratio is currently 0.03, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.03
• 2023: 0.23
• 2022: 0.18
• 2021: 0.13

Lasa Supergenerics Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Lasa Supergenerics Ltd ROE currently stands at -16.36%, showing profitability and capital efficiency.

Historical ROE:

• 2024: -16.36
• 2023: -20.22
• 2022: -28.94
• 2021: -3.37

Declining ROE indicates pressure on profitability.

Lasa Supergenerics Ltd Ratios Analysis Summary

The Lasa Supergenerics Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Lasa Supergenerics Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Lasa Supergenerics Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.